PPARG and metabolic dysfunction-associated steatotic liver disease: Thus, preventing an increase in PPARγ2 mRNA expression in HF-fed mice and in SREBP-1c and ChREBP mRNA expression in sucrose-supplemented mice, which were observed in β-conglycinin administration, contributed to the anti-NAFLD effects of β-conglycinin.